Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART-II) Trial.

Trial Profile

Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART-II) Trial.

Completed
Phase of Trial: Phase IV

Latest Information Update: 15 Aug 2012

At a glance

  • Drugs Oxybutynin; Trospium chloride
  • Indications Overactive bladder
  • Focus Pharmacodynamics; Pharmacokinetics
  • Acronyms SMART-II
  • Sponsors Allergan
  • Most Recent Events

    • 15 Aug 2012 Actual end date (Mar 2011) added as reported by ClinicalTrials.gov.
    • 02 May 2012 Results presented at the 2012 Annual Scientific Meeting of the American Geriatrics Society.
    • 31 May 2011 Planned end date changed from 1 Jan 2011 to 1 Oct 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top